Table 1.

Clinicopathological features of patients in discovery and validation phase.

Clinicopathological features	Discovery phase		Validation phase
	Papillary thyroid carcinoma (PTC) LNM-P n(%)	PTC LNN n(%)	PTC LNM-P n(%)	PTC LNN n(%)
Gender
Male	0 (0)	0 (0)	4 (57.1)	2 (50)
Female	5 (100)	5 (100)	3 (42.9)	2 (50)
Ethnic
Malay	3 (60)	4 (80)	6 (85.7)	2 (50)
Chinese	2 (40)	1 (20)	1 (14.3)	1 (25)
Indian	0 (0)	0 (0)	0 (0)	1 (25)
Age at diagnosis, year
≥45 years old	4 (80)	4 (80)	5 (71.4)	2 (50)
<45 years old	1 (20)	1 (20)	2 (28.6)	2 (50)
Mean	51.6	47.4	43.4	41.5
Tumor location
Right lobule	3 (60)	3 (60)	4 (57.1)	1 (25)
Left lobule	1 (20)	1 (20)	3 (42.9)	3 (75)
Isthmus	1 (20)	1 (20)	0 (0)	0 (0)
Tumor size (cm)
≤1	0 (0)	2 (40)	0 (0)	1 (25)
>1	5 (100)	3 (60)	7 (100)	3 (75)
BRAF V600E mutation
Positive	5 (100)	0 (0)	6 (85.7)	2 (50)
Negative	0 (0)	5 (100)	1 (14.3)	2 (50)